Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Hangqi Liu

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5069778037. Sources: OpenAlex.

Their work

Papers
4 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
12
Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 2 papers

Papers 4

  1. Tumor-Derived LAMB3 Drives Immunosuppressive LRRC15+ Fibroblast Formation During Pancreatic Ductal Adenocarcinoma Development. First author DOI 10.1002/advs.202520029↗
  2. LINC01963 promotes pancreatic ductal adenocarcinoma proliferation via METTL3/IGF2BP2 axis-mediated m⁶A modification of c-Myc. Co-author DOI 10.1186/s13046-026-03650-5↗
  3. Pancreatic stellate cells exploit Wnt/β-catenin/TCF7-mediated glutamine metabolism to promote pancreatic cancer cells growth. Co-author DOI 10.1016/j.canlet.2022.216040↗
  4. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy. Co-author DOI 10.3389/fimmu.2021.690056↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaoding Liu · 4 shared papers, 2021–2026 · strength 0.76
  2. Zhiyong Liang · 4 shared papers, 2021–2026 · strength 0.76
  3. Huanwen Wu · 3 shared papers, 2021–2026 · strength 0.52
  4. Qixian Liu · 2 shared papers, 2026 · strength 0.46
  5. Menghua Dai · 2 shared papers, 2023–2026 · strength 0.38
  6. Ruiyu Li · 2 shared papers, 2021–2023 · strength 0.30
  7. Junliang Lu · 1 shared paper, 2026 · strength 0.22
  8. Xuqing Shi · 1 shared paper, 2026 · strength 0.22
  9. Qiaofei Liu · 1 shared paper, 2023 · strength 0.16
  10. Wei‐Min Tong · 1 shared paper, 2023 · strength 0.16
  11. Hui Zhang · 1 shared paper, 2021 · strength 0.14
  12. Jing Wang · 1 shared paper, 2021 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.